Promising pneumonia therapy trial pulled before it began
NCT ID NCT07492875
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test whether adding an experimental drug and special immune cells to standard care could help critically ill adults with severe pneumonia, especially those with sepsis or lung failure. The trial was withdrawn before enrolling any participants, so no results are available. It aimed to reduce deaths within 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we optimize antibiotic dosing for children with sepsis?
- Could starting feeds sooner shield preterm babies from infection?
- Can brain waves predict thinking problems after sepsis?
- Can tailored nutrition boost recovery in the ICU?
- Blood markers may foretell brain fog after sepsis
- A hidden clue in the fingertips: could a pulse oximeter reading forecast sepsis outcomes?